ReviewAAPS PharmSciTech2026
Carbohydrate-Functionalized Liposomal Nanocarriers: Design Strategies for Receptor-Mediated Organ Targeting and Advanced Theranostic Applications.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposomes are among the most advanced drug-delivery technologies in modern nanomedicine, with high biocompatibility, structural diversity, and surface activity. They can carry both hydrophilic and lipophilic drugs. While they have been successfully applied in drug therapy to enhance pharmacokinetics and minimize systemic side effects, traditional liposomes rely on passive targeting mechanisms, including the EPR effect, to deliver drugs to targeted sites, with a high risk of non-specific distribution in the body. In contrast, carbohydrate-functionalized liposomes represent a biologically inspired drug delivery approach that utilizes the natural specificity of carbohydrate-receptor interactions to enable organ- or cell-specific drug delivery. In this review, we provide a comprehensive review of ligand selection, surface modification, conjugation chemistry, and critical quality attributes that define biological performance and robustness in drug delivery systems. Organ-specific drug delivery systems are presented, including glucose, mannose, or chitosan-functionalized liposomes for targeting the brain, galactose or N-acetylgalactosamine-based systems for targeting hepatocytes, or hyaluronic acid, fucose, or sialic acid-functionalized liposomes for targeting tumours or immune systems, respectively. Recent advancements in multi-ligand systems, stimulus-responsive systems, or biodegradable glycan surfaces have demonstrated their potential to control glycan presentation, thus controlling drug activity in drug delivery systems. In addition, challenges in glycan-based drug delivery systems, including their synthesis, stability, or safety, have been addressed, with future research directions focusing on glycomics, receptor research, or microfluidic engineering in the development of novel biomimetic drug delivery systems with disease-responsive, organ-specific, or targeted drug delivery capabilities.
Indexed as
Identifiers
42215837What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.